Thomas David Hull III Sells 213 Shares of Kewaunee Scientific Co. (NASDAQ:KEQU) Stock

Kewaunee Scientific Co. (NASDAQ:KEQU) CEO Thomas David Hull III sold 213 shares of Kewaunee Scientific stock in a transaction that occurred on Friday, March 21st. The shares were sold at an average price of $48.53, for a total transaction of $10,336.89. Following the sale, the chief executive officer now directly owns 40,916 shares of the company’s stock, valued at $1,985,653.48. This represents a 0.52 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Thomas David Hull III also recently made the following trade(s):

• On Monday, March 24th, Thomas David Hull III sold 3,000 shares of Kewaunee Scientific stock. The stock was sold at an average price of $45.63, for a total value of $136,890.00.
• On Friday, January 10th, Thomas David Hull III sold 1,368 shares of Kewaunee Scientific stock. The stock was sold at an average price of $60.08, for a total value of $82,189.44.
• On Thursday, December 26th, Thomas David Hull III sold 2,000 shares of Kewaunee Scientific stock. The shares were sold at an average price of $63.01, for a total value of $126,020.00.

Kewaunee Scientific Stock Performance

Shares of NASDAQ:KEQU opened at $40.60 on Wednesday. The firm has a 50 day moving average of $56.95 and a 200 day moving average of $47.55. The company has a quick ratio of 2.13, a current ratio of 2.64 and a debt-to-equity ratio of 0.45. The company has a market capitalization of $115.91 million, a price-to-earnings ratio of 6.43 and a beta of 0.71. Kewaunee Scientific Co. has a 52 week low of $30.82 and a 52 week high of $71.33.

Kewaunee Scientific (NASDAQ:KEQU) last released its quarterly earnings results on Wednesday, March 12th. The technology company reported $1.09 EPS for the quarter. Kewaunee Scientific had a return on equity of 25.83% and a net margin of 9.39%. The firm had revenue of $67.17 million during the quarter.

Institutional Trading of Kewaunee Scientific

Several hedge funds have recently modified their holdings of the company. De Lisle Partners LLP lifted its position in Kewaunee Scientific by 36.6% during the third quarter. De Lisle Partners LLP now owns 42,958 shares of the technology company’s stock valued at $1,446,000 after acquiring an additional 11,511 shares during the last quarter. State Street Corp acquired a new position in shares of Kewaunee Scientific during the third quarter worth $266,000. Barclays PLC purchased a new stake in shares of Kewaunee Scientific during the 3rd quarter valued at $121,000. Geode Capital Management LLC boosted its position in shares of Kewaunee Scientific by 8.9% in the 3rd quarter. Geode Capital Management LLC now owns 23,784 shares of the technology company’s stock worth $792,000 after purchasing an additional 1,941 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its stake in Kewaunee Scientific by 18,000.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 905 shares of the technology company’s stock worth $30,000 after buying an additional 900 shares during the last quarter. 32.69% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, StockNews.com downgraded shares of Kewaunee Scientific from a “buy” rating to a “hold” rating in a research report on Friday, March 14th.

Kewaunee Scientific Company Profile

Kewaunee Scientific Corporation designs, manufactures, and installs laboratory, healthcare, and technical furniture and infrastructure products. The company operates through two segments, Domestic and International. Its products include steel and wood casework, fume hoods, adaptable modular systems, moveable workstations, stand-alone benches, biological safety cabinets, and epoxy resin work surfaces and sinks.